These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
799 related articles for article (PubMed ID: 8221449)
41. The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants. Mulholland EK; Byass P; Campbell H; Fritzell B; Greenwood AM; Todd J; Greenwood BM Ann Trop Paediatr; 1994; 14(3):183-8. PubMed ID: 7825990 [TBL] [Abstract][Full Text] [Related]
42. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Eskola J; Olander RM; Hovi T; Litmanen L; Peltola S; Käyhty H Lancet; 1996 Dec 21-28; 348(9043):1688-92. PubMed ID: 8973430 [TBL] [Abstract][Full Text] [Related]
43. Neonatal immunization: response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Kurikka S; Käyhty H; Peltola H; Saarinen L; Eskola J; Mäkelä PH Pediatrics; 1995 Jun; 95(6):815-22. PubMed ID: 7761204 [TBL] [Abstract][Full Text] [Related]
44. Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Hoppenbrouwers K; Kanra G; Roelants M; Ceyhan M; Vandermeulen C; Yurdakök K; Silier T; Dupuy M; Pehlivan T; Ozmert E; Desmyter J Vaccine; 1999 Feb; 17(7-8):875-86. PubMed ID: 10067694 [TBL] [Abstract][Full Text] [Related]
45. Safety and immunogenicity of Haemophilus influenzae type B vaccine given in combination with DTwP at 6, 10 and 14 weeks of age. Cherian T; Thomas N; Raghupathy P; Durot I; Dutta A Indian Pediatr; 2002 May; 39(5):427-36. PubMed ID: 12037271 [TBL] [Abstract][Full Text] [Related]
46. Adverse reactions to the preschool (fifth) dose of adsorbed diphtheria-pertussis-tetanus vaccine in Canadian children. Scheifele DW; Meekison W; Grace M; Barreto L; Carter AO; Mitchell L; Farley J CMAJ; 1991 Sep; 145(6):641-7. PubMed ID: 1893319 [TBL] [Abstract][Full Text] [Related]
47. Safety and immunogenicity of 2 mixed primary infant immunization schedules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae Type B vaccines at 2, 4, and 6 months of age: a randomized controlled trial. Langley JM; Halperin SA; Rubin E; White C; McNeil S; Mutch J; Mackinnon-Cameron D; Smith B Pediatr Infect Dis J; 2012 Feb; 31(2):189-92. PubMed ID: 22173143 [TBL] [Abstract][Full Text] [Related]
48. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. Clemens JD; Ferreccio C; Levine MM; Horwitz I; Rao MR; Edwards KM; Fritzell B JAMA; 1992 Feb; 267(5):673-8. PubMed ID: 1731134 [TBL] [Abstract][Full Text] [Related]
49. Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand. Thisyakorn U; Chotpitayasunondh T; Pancharoen C; Chuenkitmongkol S; Ortiz E Southeast Asian J Trop Med Public Health; 2010 Mar; 41(2):450-62. PubMed ID: 20578530 [TBL] [Abstract][Full Text] [Related]
50. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Schmitt HJ; Zepp F; Müschenborn S; Sümenicht G; Schuind A; Beutel K; Knuf M; Bock HL; Bogaerts H; Clemens R Eur J Pediatr; 1998 Mar; 157(3):208-14. PubMed ID: 9537487 [TBL] [Abstract][Full Text] [Related]
51. Associated or combined vaccination of Brazilian infants with a conjugate Haemophilus influenzae type b (Hib) vaccine, a diphtheria-tetanus-whole-cell pertussis vaccine and IPV or OPV elicits protective levels of antibodies against Hib. Araújo OO; Forleo-Neto E; Vespa GN; Puccini RF; Weckx LW; Carvalho ES; Farhat CK Vaccine; 2000 Sep; 19(2-3):367-75. PubMed ID: 10930692 [TBL] [Abstract][Full Text] [Related]
52. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. Granoff DM; Holmes SJ; Belshe RB; Osterholm MT; McHugh JE; Anderson EL JAMA; 1994 Oct; 272(14):1116-21. PubMed ID: 7933324 [TBL] [Abstract][Full Text] [Related]
53. Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Gold R; Scheifele D; Barreto L; Wiltsey S; Bjornson G; Meekison W; Guasparini R; Medd L Pediatr Infect Dis J; 1994 May; 13(5):348-55. PubMed ID: 8072815 [TBL] [Abstract][Full Text] [Related]
54. Immunogenicity and safety of Haemophilus influenzae type b-tetanus protein conjugate vaccine alone or mixed with diphtheria-tetanus-pertussis vaccine in infants. Kaplan SL; Lauer BA; Ward MA; Wiedermann BL; Boyer KM; Dukes CM; Schaffer DM; Paisley J; Mendelson R; Pedreira F J Pediatr; 1994 Feb; 124(2):323-7. PubMed ID: 8301447 [TBL] [Abstract][Full Text] [Related]
55. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age. Ferreccio C; Clemens J; Avendano A; Horwitz I; Flores C; Avila L; Cayazzo M; Fritzell B; Cadoz M; Levine M Pediatr Infect Dis J; 1991 Oct; 10(10):764-71. PubMed ID: 1945579 [TBL] [Abstract][Full Text] [Related]
56. A comparative study to evaluate the safety and immunogenicity of two lots of Haemophilus influenzae type-B conjugate vaccine manufactured at different scales. Hirve S; Bavdekar A; Juvekar S; Agarwal D; Barde P; Mangrule S; Patwardhan M; Pandit A; Kulkarni PS Vaccine; 2011 Jul; 29(33):5363-7. PubMed ID: 21651947 [TBL] [Abstract][Full Text] [Related]
57. Immunogenicity of Haemophilus influenzae type b capsular polysaccharide vaccines in 18-month-old infants. Hendley JO; Wenzel JG; Ashe KM; Samuelson JS Pediatrics; 1987 Sep; 80(3):351-4. PubMed ID: 3306597 [TBL] [Abstract][Full Text] [Related]
58. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants. Paradiso PR; Hogerman DA; Madore DV; Keyserling H; King J; Reisinger KS; Blatter MM; Rothstein E; Bernstein HH; Hackell J Pediatrics; 1993 Dec; 92(6):827-32. PubMed ID: 8233745 [TBL] [Abstract][Full Text] [Related]
59. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Dagan R; Igbaria K; Piglansky L; Melamed R; Willems P; Grossi A; Kaufhold A Pediatr Infect Dis J; 1997 Dec; 16(12):1113-21. PubMed ID: 9427455 [TBL] [Abstract][Full Text] [Related]
60. Safety and immunogenicity of Haemophilus influenzae type b-tetanus toxoid conjugate, presented in a dual-chamber syringe with diphtheria-tetanus-pertussis and inactivated poliomyelitis combination vaccine. Langue J; Ethevenaux C; Champsaur A; Fritzell B; Bégué P; Saliou P Eur J Pediatr; 1999 Sep; 158(9):717-22. PubMed ID: 10485302 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]